IDEXX Laboratories, Inc. $IDXX Holdings Raised by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 209,106 shares of the company’s stock after purchasing an additional 8,626 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in IDEXX Laboratories were worth $141,466,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after purchasing an additional 86,040 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in IDEXX Laboratories by 41.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after acquiring an additional 605,290 shares in the last quarter. Invesco Ltd. lifted its stake in IDEXX Laboratories by 14.0% in the 3rd quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock worth $843,503,000 after acquiring an additional 161,782 shares in the last quarter. Principal Financial Group Inc. lifted its stake in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after acquiring an additional 187,967 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after acquiring an additional 326,348 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at $6,352,730.56. This trade represents a 53.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Price Performance

IDXX opened at $563.00 on Monday. IDEXX Laboratories, Inc. has a fifty-two week low of $375.05 and a fifty-two week high of $769.98. The business has a 50-day moving average of $607.41 and a 200-day moving average of $656.92. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The company has a market capitalization of $44.72 billion, a PE ratio of 43.08, a price-to-earnings-growth ratio of 3.42 and a beta of 1.72.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business earned $2.53 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on IDXX shares. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $772.22.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.